Global Information
회사소개 | 문의 | 위시리스트

세계의 안검염 치료제 시장(2019-2023년)

Global Blepharitis Drugs Market 2019-2023

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2019년 07월 상품 코드 900618
페이지 정보 영문 124 Pages
가격
US $ 2,500 ₩ 3,001,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,601,000 PDF by E-mail (5-user License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,802,000 PDF by E-mail (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 6,002,000 PDF by E-mail (Global License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 안검염 치료제 시장(2019-2023년) Global Blepharitis Drugs Market 2019-2023
발행일 : 2019년 07월 페이지 정보 : 영문 124 Pages

안검염 치료제에는 눈꺼풀의 염증과 감염증 치료에 사용되는 스테로이드와 항생물질이 포함됩니다. 세계 안검염 치료제 시장은 2018년에는 스테로이드 부문이 가장 높은 시장 점유율을 기록했으며, 이러한 경향은 예측기간 동안 계속될 것으로 예상됩니다. 또 안검염 치료제 시장은 안검염의 고위험인자, 눈 상태에 관한 의식 고양, 병용약 사용 증가 등이 시장 성장 촉진요인이 되어 예측기간 중 5% 이상의 연평균 복합 성장률(CAGR)로 확대될 전망입니다. 하지만 인가를 획득한 안검염 치료제 부족, 항균제 내성, 신규 치료법 개발 등의 요인이 예측기간 중 안검염 치료제 시장의 성장을 방해할 가능성이 있습니다.

세계의 안검염 치료제(Blepharitis Drugs) 시장에 대해 조사 분석했으며, 시장 규모 및 성장률, 시장 동향, 시장 성장 촉진요인과 과제, 시장 기회, 주요 벤더 등에 대한 체계적인 정보를 제공합니다.

목차

제1장 주요 요약

제2장 조사 범위

  • 서론 1
  • 서론 2
  • 달러의 통화 환산율

제3장 시장 상황

  • 시장 생태계
  • 시장의 특징
  • 시장 세분화 분석

제4장 시장 규모

  • 시장 정의
  • 시장 규모(2018년)
  • 시장 규모 및 예측(2018-2023년)

제5장 Five Forces 분석

  • 구매자의 협상력
  • 공급업체의 협상력
  • 신규 참여업체의 위협
  • 대용품의 위협
  • 경쟁사의 위협
  • 시장 현황

제6장 시장 세분화 : 제품별

  • 시장 세분화 : 제품별
  • 제품별 비교 : 시장 규모 및 예측(2018-2023년)
  • 스테로이드
  • 항생물질
  • 시장 기회 : 제품별

제7장 고객 상황

제8장 지역별 상황

  • 지역별 세분화
  • 지역별 비교
  • 북미
  • 유럽
  • 아시아
  • 기타 지역
  • 주요 국가
  • 시장 기회

제9장 성장요인과 과제

  • 시장 성장요인
  • 시장의 과제

제10장 시장 동향

제11장 벤더 상황

  • 개요
  • 파괴적 혁신

제12장 벤더 분석

  • 대상 벤더
  • 벤더 분류
  • 벤더의 시장 포지셔닝
  • Akorn Inc.
  • Allergan Plc
  • Bausch Health Companies Inc.
  • Novartis AG
  • Pfizer Inc.

제13장 부록

  • 조사 방법
  • 약어 리스트
  • 벤더의 시장 포지셔닝 정의

제14장 TECHNAVIO에 대해

LSH 19.08.13

About this market

Blepharitis drugs include steroids and antibiotics, which are used to treat inflammation in the eyelids and infection. Technavio's blepharitis drugs market analysis considers sales from the steroids and antibiotics segments. Our analysis also considers the sales of blepharitis drugs in Asia, Europe, North America, and ROW. In 2018, the steroids segment held the highest market share, which is expected to remain prevalent over the forecast period. Factors such as the expected approval of late-stage molecules and the high efficacy of steroids in treating inflammations in the eyelids will significantly help the market segment in maintaining its leading position. Also, our global blepharitis drugs report has observed market growth factors such as high-risk factors of blepharitis, growing awareness about eye conditions, and increasing use of combination drugs. However, lack of approved therapies to treat blepharitis, antimicrobial resistance, and development of novel treatment procedures may hamper the growth of the blepharitis drugs industry over the forecast period.

Overview

Increasing use of combination drugs

The use of combination of off-label steroids and antibiotics is increasing to treat blepharitis owing to the lack of availability of approved therapies and their proven advantages over monotherapy. As a result, vendors are recording increased sales, which will contribute to the growth of the market over the forecast period. The blepharitis drugs market will record a CAGR over 5% during 2019-2023.

Development of novel drug formulations

Although antibiotics and steroids are commonly used for the symptomatic treatment of blepharitis, there is a high unmet need for novel therapies with high efficacy and fewer side-effects. As a result, vendors have a significant growth potential in the market and have started developing novel therapeutics. Therefore, this trend will have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global blepharitis drugs market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global blepharitis drugs market is fragmented. Technavio's robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of several leading blepharitis drugs manufacturers, which include Akorn Inc., Allergan Plc, Bausch Health Companies Inc., Novartis AG, and Pfizer Inc.

Also, the blepharitis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Steroids - Market size and forecast 2018-2023
  • Antibiotics - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 12: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Akorn Inc.
  • Allergan Plc
  • Bausch Health Companies Inc.
  • Novartis AG
  • Pfizer Inc.

PART 13: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 14: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Steroids - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Steroids - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Antibiotics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Antibiotics - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by product
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Top 3 countries in North America
  • Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in Europe
  • Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Asia
  • Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in ROW
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Some of the combination drugs available in the market
  • Exhibit 43: Impact of drivers and challenges
  • Exhibit 44: Recent strategic alliances in ophthalmology:
  • Exhibit 45: Vendor landscape
  • Exhibit 46: Landscape disruption
  • Exhibit 47: Vendors covered
  • Exhibit 48: Vendor classification
  • Exhibit 49: Market positioning of vendors
  • Exhibit 50: Akorn Inc. - Vendor overview
  • Exhibit 51: Akorn Inc. - Business segments
  • Exhibit 52: Akorn Inc. - Organizational developments
  • Exhibit 53: Akorn Inc. - Segment focus
  • Exhibit 54: Akorn Inc. - Key offerings
  • Exhibit 55: Akorn Inc. - Key customers
  • Exhibit 56: Allergan Plc - Vendor overview
  • Exhibit 57: Allergan Plc - Product segments
  • Exhibit 58: Allergan Plc - Organizational developments
  • Exhibit 59: Allergan Plc - Geographic focus
  • Exhibit 60: Allergan Plc - Segment focus
  • Exhibit 61: Allergan Plc - Key offerings
  • Exhibit 62: Allergan Plc - Key customers
  • Exhibit 63: Bausch Health Companies Inc. - Vendor overview
  • Exhibit 64: Bausch Health Companies Inc. - Business segments
  • Exhibit 65: Bausch Health Companies Inc. - Organizational developments
  • Exhibit 66: Bausch Health Companies Inc. - Geographic focus
  • Exhibit 67: Bausch Health Companies Inc. - Segment focus
  • Exhibit 68: Bausch Health Companies Inc. - Key offerings
  • Exhibit 69: Bausch Health Companies Inc. - Key customers
  • Exhibit 70: Novartis AG - Vendor overview
  • Exhibit 71: Novartis AG - Business segments
  • Exhibit 72: Novartis AG - Organizational developments
  • Exhibit 73: Novartis AG - Geographic focus
  • Exhibit 74: Novartis AG - Segment focus
  • Exhibit 75: Novartis AG - Key offerings
  • Exhibit 76: Novartis AG - Key customers
  • Exhibit 77: Pfizer Inc. - Vendor overview
  • Exhibit 78: Pfizer Inc. - Business segments
  • Exhibit 79: Pfizer Inc. - Organizational developments
  • Exhibit 80: Pfizer Inc. - Geographic focus
  • Exhibit 81: Pfizer Inc. - Segment focus
  • Exhibit 82: Pfizer Inc. - Key offerings
  • Exhibit 83: Pfizer Inc. - Key customers
  • Exhibit 84: Validation techniques employed for market sizing
  • Exhibit 85: Definition of market positioning of vendors
Back to Top
전화 문의
F A Q